Bonus BioGroup Ltd. (BBIXF)

Market Cap	58.40M -25.3%
Revenue (ttm)	n/a
Net Income	-8.01M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.0200
Previous Close	0.0500
Day's Range	0.0200 - 0.0500
52-Week Range	0.0300 - 0.1500
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Bonus BioGroup

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 42
• Stock Exchange: OTCMKTS
• Ticker Symbol: BBIXF

Financial Performance

Financial numbers in ILS

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error